Advik Pharmaa Peer Comparison

BSE: 531686

₹2.08

₹0.09 (4.52%)

As on 15-Sep-2026IST

Market cap

₹4 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

-22.3

Div. Yield

0 %

Edit

	Advik Pharmaa	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	4	38,241	29,349	17,570	15,629
Revenue (₹ Cr)	--	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	-1.04	1,018.97	497.77	603.02	270.18
Net Margin (%)	-2,886.11	10.47	20.72	22.63	23.29
RoE (%)	-291.44	21.30	28.49	19.61	14.45
Price to Earnings	--	37.81	58.96	29.14	56.75
Price-To-Book	-22.29	7.31	14.52	5.04	7.54

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Advik Pharmaa	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	0.00	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	0.04	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	0.96	7,739.53	1,608.91	1,753.71	720.01
EBITDA	-0.96	1,943.92	762.90	836.69	388.38
Depreciation	0.15	425.10	98.11	78.88	74.78
EBIT	-1.10	1,518.82	664.79	757.81	313.60
Interest	0.00	148.45	26.33	5.43	0.26
Other Income	0.04	47.39	30.80	73.83	51.50
Exceptional Items	0.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	-1.07	1,389.91	669.26	800.55	361.56
Provision for Tax	-0.03	370.94	171.48	197.53	91.39
Profit after Tax	-1.04	1,018.97	497.77	603.02	270.18

Liabilities (₹ Cr)

	Advik Pharmaa	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	0.07	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	0.22	723.57	345.47	142.73	50.51
Current Liabilities	8.19	3,912.24	710.20	508.04	169.08
Total Liabilities	9.33	8,121.73	2,179.88	3,753.59	2,034.25

Assets (₹ Cr)

	Advik Pharmaa	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	6.61	3,392.16	1,290.62	1,321.38	957.22
Current Assets	1.87	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	9.33	8,121.73	2,179.88	3,753.59	2,034.25
Total Debt*	7.46	731.70	136.01	0.00	0.38
Net Current Assets	-6.32	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	0.04	393.94	8.97	4.82	3.91

Cashflow (₹ Cr)

	Advik Pharmaa	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-0.57	851.71	317.40	391.52	244.52
Cash Flow from Investing Activities	0.38	-94.00	-298.16	-615.65	-159.99
Cash from Financing Activities	0.18	-813.96	24.96	-6.23	-98.77
Net Cash Inflow / Outflow	0.00	-56.25	44.21	-230.35	-14.24

Ratios

Profitability Ratios

	Advik Pharmaa	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	-9.70	22.49	23.45	25.50	29.62
ROE (%)	-291.44	21.30	28.49	19.61	14.45
ROA (%)	-11.67	11.42	19.48	16.31	12.66
EBIT Margin (%)	--	15.68	28.03	29.25	28.29
Net Margin (%)	-2,886.11	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	--	0.00	0.00	0.00	0.00

Growth Ratios

	Advik Pharmaa	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	--	18.36	78.33	7.93	-6.72
EBIT Growth (%)	-21.48	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	-15.96	32.39	182.61	21.66	-24.38
EPS Growth (%)	-15.96	36.68	277.72	25.42	-21.99
Book Value Growth (%)	-45.11	50.94	18.89	20.94	18.74

Valuation Ratios

	Advik Pharmaa	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	0.00	37.03	58.96	28.21	56.26
Price / Book Value	5.62	7.31	14.52	5.04	7.54
Dividend Yield (%)	0.00	0.18	0.15	0.35	0.51
EV/EBITDA	-18.91	20.22	38.26	20.06	39.17
Market Cap (₹ Cr)	--	20,327.45	15,494.53	13,228.83	17,537.35

Solvency Ratios

	Advik Pharmaa	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.00	0.05	0.09	0.00	0.00
Short term debt to equity ratio	6.90	0.11	--	--	0.00
Current Ratio	0.23	1.43	2.09	5.21	7.39
Quick Ratio	0.19	0.82	1.37	3.85	5.46
Interest Coverage	-1,067.00	10.36	26.41	148.49	1,386.30

Operating Efficiency Ratios

	Advik Pharmaa	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	--	26.46	22.82	41.42	41.52
Asset Turnover	0.00	1.09	0.93	0.70	0.52
Receivable days	--	87.83	85.17	132.12	132.49
Inventory Days	--	78.64	90.97	102.08	68.07
Payable days	--	174.97	137.94	133.54	123.94
Cash Conversion Cycle	--	-8.50	38.21	100.66	76.63

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly